A Phase I Trial of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35)

NCT00779883 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

9

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Lymphocytic Leukemia

Interventions

BIOLOGICAL: ISF35

Sponsor

Memgen, LLC